Healer

In August 2026, Healer remained concentrated in Tincture & Sublingual at 86.05% share, where sales fell 53.94% year over year but rose 13.87% month over month, while brand-wide sales declined 49.53% year over year and the average price increased 32.93%. Topical held 5.95% share with a 10.65% year-over-year decline but a 55.77% month-over-month increase, and Edible at 2.46% share slipped 40.50% year over year with a 0.28% month-over-month dip; Capsules expanded to 5.53% share with a 986.58% year-over-year jump but no reported month-over-month figure. With an average price of $36.15 against category prices of $35.50 for Tincture & Sublingual and $53.56 for Topical, the mix skews toward a lower-priced anchor despite price inflation, implying that August 2026 performance hinged on a recovering core (up 13.87% MoM) offset by deep year-over-year attrition in that same core (down 53.94% YoY) and a small, fast-growing Capsules foothold.

Healer’s number 1 rank in Tincture & Sublingual in Maryland alongside an 86.05% mix weight indicates positioning as a category specialist, but the 53.94% year-over-year decline in that category and a 49.53% brand-level contraction suggest overexposure risk unless mix diversification persists. The 55.77% month-over-month lift in Topical and the 986.58% year-over-year surge in Capsules provide optionality to rebalance toward higher-price segments, yet the 0.28% month-over-month dip in Edible and a 40.50% year-over-year decline limit breadth; the pattern implies that short-term stability depends on sustaining double-digit month-over-month gains outside Tincture & Sublingual while defending the Maryland rank to keep the core from dragging total performance.